Trial Profile

Safety and Efficacy Phase I/IIa Trial of an RNActive-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 21 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CV 9201 (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions; First in man; Pharmacodynamics; Therapeutic Use
Sponsors CureVac

Most Recent Events

01 May 2019 Results published in the Cancer Immunology Immunotherapy
18 Sep 2014 Results published in a Boehringer Ingelheim and CureVac media release.
24 Oct 2012 Planned number of patients changed from 33 to 46 as reported by EudraCT record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com